Trial · NCT05336175
Biomarker Study: Heart Failure Patients at Risk
NCT05336175, Phase 1, Phase 2, Unknown, University of Arizona
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Biomarker Study: Heart Failure Patients at Risk. Trials, record NCT05336175. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05336175
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Biomarker Study: Heart Failure Patients at Risk
- NCT number
- NCT05336175
- Status
- Unknown
- Phases
- Phase 1, Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- University of Arizona
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
- Interventions
- Angiotensin 1-7, Saline solution
- First posted
- 2022-04-20
- Last updated
- 2022-04-20
Source ClinicalTrials.gov
Registered outcomes42
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Baseline Blood Biomarkers - Neurology 4-Pleax A, pTau-181, and pTau 231 as measured by the Quanterix Simoa Neurology 4-plex A and Simoa pTau-181 and 283 advantage kits | These measurements will be taken at baseline | We will use the Quanterix Simoa Neurology 4-Plex A (N4PA) Advantage kit to measure Neurology 4-Plex A (GFAP, NF-light, Total Tau, UCH-L1 and the Simoa pTau-181 and 283 Advantage kits to measure pTau-181 and pTau 231. |
| Primary | Baseline evaluations of associative, verbal memory as measured by the verbal paired associates task (version 2) | These measurements will be taken at baseline | The verbal paired associates task (version 2) will be used to evaluate associative, verbal memory. Scores can range from 0 to 36 with higher scores indicating better outcomes. |
| Primary | Baseline evaluations of associative, visual memory as measured by the Face Name Associative Memory Test | These measurements will be taken at baseline | The Face Name Associative Memory Test will be used to evaluate associative, visual memory. Scores can range from 0 to 12 with higher scores indicating better outcomes. |
| Primary | Baseline evaluations of pattern separation memory as measured by the Mnemonic Similarity Task | These measurements will be taken at baseline | The Mnemonic Similarity Task will be used to evaluate pattern separation memory. Scores can range from 0 to 1.0 with higher scores indicating better outcomes |
| Primary | Baseline evaluations of executive functions - updating/working memory as measured by the Keep Track Task | These measurements will be taken at baseline | The Keep Track Task will be used to evaluate executive function - updating/working memory. Scores can range from 0 to 30 with higher scores indicating better performance. |
| Primary | Baseline evaluations of executive functions - switching as measured by the Number-Letter Task | These measurements will be taken at baseline | The Number-Letter task will be used to evaluate executive function - switching. Scores can range from 0.2sec to 10 sec with higher scores indicating worse outcomes |
| Primary | Baseline evaluations of executive functions - attention/inhibition as measured by the Flanker Task | These measurements will be taken at baseline | The Flanker Task will be used to evaluate executive function - attention/inhibition. Scores can range from 200ms - 2000ms with higher scores indicating worse outcomes |
| Primary | Baseline evaluations of processing speeds - simple/complex processing speeds as measured by the Deary-Liewald Reaction Time Task | These measurements will be taken at baseline | The Deary-Liewald Reaction Time Task will evaluate processing speed - simple/complex processing speed. Scores can range from 200ms - 1500ms with higher scores indicating worse outcomes |
| Primary | Baseline evaluations of reading ability/vocabulary as measured by the North American Reading Test | These measurements will be taken at baseline | The North American Reading Test will be used to evaluate reading ability/vocabulary. Scores can range from 0 to 61 with higher score indicating better outcomes |
| Primary | Baseline evaluations of global cognitive functioning as measured by the Montreal Cognitive Assessment | These measurements will be taken at baseline | The Montreal Cognitive Assessment will be used to evaluate global cognitive functioning/ Scores can range from 0 - 30 with higher scores indicating better outcomes. |
1 to 10 of 42Source ClinicalTrials.gov
See all 42 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Eriksen Flanker Task | Primary outcome | ConductCognition |
| Face-name Memory Task | Primary outcome | ConductCognition |
| Keep-Track Task | Primary outcome | ConductCognition |
| Mnemonic Similarity Task | Primary outcome | ConductCognition |
| Word Pair Learning | Primary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05336175
GET https://conductscience.org/api/trials/v1/NCT05336175/registered?page=2